Severe Erythema Multiforme - CORTICO

NCT06266221 | Not Yet Recruiting Phase 3 DMC

• 2 other identifiers: APHP2000732022-000712-59
• Study Type: interventional
• Target: 96
• Locations: 0 countries
• Sites: N/A

Brief Summary

Erythema multiforme (EM) is an acute and often recurrent mucocutaneous disease. EM is considered a hypersensitivity immune-mediated reaction. The two main known triggering factors are Herpes simplex virus (HSV) and Mycoplasma pneumoniae (MP) infections. Typical target skin lesions characterize EM, especially oral MMs. EM is in fact mainly linked to the oral MM involvement, including intense mucosal pain, impaired food intake, weight loss, hospitalization and potential risk of fibrotic sequelae (oral, ocular, genital, oesophageal, respiratory tract) and recurrences. The objectives of treatment for severe EM in the acute phase are to reduce the duration of lesions, prevent complications and mucosal sequelae. However, despite the lack of evidence and consensus some medical teams often use a short regimen of SCS hoping to obtain a quicker improvement of the condition. However, the use of SCS at the acute phase is not codified and remains debated according to the existent literature. Current studies are mostly retrospective and based on small cohorts or case reports. A randomized, controlled trial would be therefore essential to properly evaluate the benefit of SCS in this pathology and provide strong support to clinicians in their decision making in severe EM during the acute phase. This research will be a Phase III randomized, multicentric, double-blind, controlled trial with two parallel groups. The efficacy of prednisone, oral at 1 mg/kg/day for 3 days, tapered to 0.75 mg/kg/day for 3 days, 0.50 mg/kg/day for 3 days, 0.25 mg/kg/day for 3 days is compared to that of placebo, oral for 12 days or IV methylprednisolone if oral route is impossible because of the self-reported inability for the patient to swallow due to the impacts of the oral lesions, with dosage equivalence at 0.8 mg/kg/day for 3 days, tapered to 0.6 mg/kg/day for 3 days, 0.4 mg/kg/day for 3 days, 0.2 mg/kg/day for 3 days, then stopped, compared to that of placebo. A stratification according to the food intake classification (0,1,2 vs 3) will be performed. An interim analysis is planned after the inclusion of 50 patients. Results of the interim analysis will be presented to the DSMB. During the interim analysis, inclusions may continue.

Conditions

Erythema Multiforme

Keywords

Erythema; Corticoids; Prednisone; Methylprednisolone

Outcome Measures

Primary Outcomes (4)

• Time to success

  It will be defined by controlled pain (Numeric Rating Scale (NR, range 0-10) score \<4 and sustained no need for any level III analgesics, during 48 hours), resumption of non-blended food intake and no need for rescue therapy (IV methylprednisolone at 1mg/kg/day with discontinuation of the current treatment in both arms).

  Day0 to Month1

• Evaluation of Pain

  It will be evaluated daily by using the NR (0-10), 3 times a day during hospitalization and once a day (worst score of the day) after the hospitalization by phone until achievement of the primary end-point. To avoid confounding bias, management of pain will be standardized: Level I, II and III analgesics will be permitted during the treatment, but analgesics taken will be reported and the success is defined as no need for any level III analgesics.

  Day0 to Month1

• Food intake

  It will be evaluated qualitatively daily by the investigator team (eg. investigator or collaborator, dietician, trained clinical study technician) by use of a standardized questionnaire. Food intake will be classified as the following categories: 0, impossible to eat; 1, liquid food possible; 2, mixed food possible; 3, chopped food possible; 4, solid food possible. For patient with categories 0, 1 or 2 at baseline, the success will be defined by the resump-tion of categories 3 or 4. For patients with category 3 at baseline, the success will be catego-ry 4. A subgroup analysis will be performed considering the two food intake classification strata.

  Day0 to Month1

• Rescue therapy intake

  The rescue therapy will be standardized for all patients in failure of the initial strategy and will be: IV methylprednisolone at 1 mg/kg/day with discontinuation of the current treatment in both arms.

  From Day 0 until discharge from hospital, assessed up to Day 15

Secondary Outcomes (10)

• Time to clear or almost clear healing of all sites

  Day15 and Month1

• Time to fever resolution

  From Day 0 until discharge from hospital, assessed up to Day 15

• Length of hospital stay

  From Day 0 until discharge from hospital, assessed up to Day 15

• Number of days of consumption of level III analgesics

  From Day 0 until complete healing, assessed up to Month 1

• Evaluation of pain

  From Day 0 until complete healing, assessed up to Month 1

Study Arms (2)

Systemic Corticosteroids

EXPERIMENTAL

Oral prednisone at 1 mg/kg/day for 3 days, tapered to 0.75 mg/kg/day for 3 days, 0.50 mg/kg/day for 3 days, 0.25 mg/kg/day for 3 days. If the oral route is not possible, IV methylprednisolone will be used at 0.8 mg/kg/day for 3 days, ta-pered to 0.6 mg/kg/day for 3 days, 0.4 mg/kg/day for 3 days, 0.2 mg/kg/day for 3 days (equivalent predni-sone dosage). In the event of a change of route administration (IV then Oral or Oral then IV), the posology of prednisone or methylprednisolone or placebo will correspond to the dosage equivalent to that prescribed at the time of the switch.

Drug: Prednisone 20 Mg; Drug: Methylprednisolone 120 Mg

Placebo

PLACEBO COMPARATOR

Oral or IV placebo with the same decrease of dose: same number of tablets for prednisone placebo and same volume as methylprednisolone for its placebo

Drug: Oral Placebo; Drug: IV Placebo

Interventions

Prednisone 20 Mg DRUG

Oral corticosteriods

Also known as: Oral corticosteriods

Systemic Corticosteroids

Oral Placebo DRUG

Oral placebo

Also known as: placebo

Placebo

Methylprednisolone 120 Mg DRUG

IV corticosteriods

Also known as: IV corticosteriods

Systemic Corticosteroids

IV Placebo DRUG

IV placebo

Also known as: placebo

Placebo

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 15 years old and 30 kg ≤ Weight ≤ 150 kg
• Clinical diagnosis of severe EM defined as:
• Two or more MMs affected (mouth, throat, eyes, ear, nose, genital and/or anal areas), or only the oral MM affected, if severely affected (score\* 2 or 3 of Harman criteria22) with altered general conditions and significant impact on food intake (solid food impossible)
• First flare of EM or acute recurrence of previously diagnosed EM
• Disease flare that has lasted for up to 5 days (≤5 days)
• Affiliated to a social security scheme
• Able to provide written informed consent; consent of both parents will be col-lected for minors
• score: 1, minor activity (up to three erosions); 2, moderate activity (more than three but less than 10 erosions, or generalized desquamative gingivitis); 3, severe (more than 10 discrete erosions or extensive, confluent erosions, or generalized desquamative gingivi-tis with discrete erosions at other oral sites).

You may not qualify if:

• EM without involvement of oral cavity compromising normal solid food
• Patients unable to eat solid food outside of their current pathology (erythema multiforme)
• Other diagnosis potentially involving MMs: Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), pemphigus, herpetic gingivostomatitis
• Use of systemic Corticosteroids for \> 5 days for any previous flare of EM (\>10mg),
• Contraindication to systemic Corticosteroids:
• hypersensitivity to systemic Corticosteroids or to an excipient;
• uncontrolled primary bacterial, viral, fungal or parasitic infection
• psychotic states not yet controlled by treatment
• Sepsis (shock, cyanosis, hypothermia, low blood pressure monitored succes-sively twice (systemic blood pressure \< 90 mmHg and diastolic blood pres-sure \< 60 mmHg)
• Kidney or liver insufficiency (creatinine level ≥ 150 µmol/L; aspartate ami-notransferase or alanine aminotransferase level \> 3 times the upper limit of normal)
• Current cancer with the exception of non-metastatic skin carcinoma not re-quiring immediate medical treatment
• Pregnant or breastfeeding
• Person subject to safeguards of justice
• Person deprived of liberty by judicial or administrative decision
• Person subject to psychiatric care without their consent

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

MeSH Terms

Conditions

Erythema Multiforme; Erythema

Interventions

Prednisone; Methylprednisolone

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Vesiculobullous; Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Prednisolone; Pregnadienetriols

Study Officials

• Candy Estevez, M.Sc

  APHP

  STUDY CHAIR

Central Study Contacts

Saskia Oro, PhD

CONTACT

01 49 81 25 01; saskia.oro@aphp.fr

Olivier Chosidow, PhD

CONTACT

olivier.chosidow@aphp.fr

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 11, 2023
• First Posted: February 20, 2024
• Study Start: May 1, 2024
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: February 20, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share